Evidence that glycogen synthase kinase-3 isoforms have distinct substrate preference in the brain

Marc P.M. Soutar, Woo Yang Kim, Ritchie Williamson, Mark Peggie, Charles James Hastie, Hilary McLauchlan, William D. Snider, Phillip R. Gordon-Weeks, Calum Sutherland

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

Mammalian glycogen synthase kinase-3 (GSK3) is generated from two genes, GSK3α and GSK3β, while a splice variant of GSK3β (GSK3β2), containing a 13 amino acid insert, is enriched in neurons. GSK3α and GSK3β deletions generate distinct phenotypes. Here, we show that phosphorylation of CRMP2, CRMP4, β-catenin, c-Myc, c-Jun and some residues on tau associated with Alzheimer's disease, is altered in cortical tissue lacking both isoforms of GSK3. This confirms that they are physiological targets for GSK3. However, deletion of each GSK3 isoform produces distinct substrate phosphorylation, indicating that each has a different spectrum of substrates (e.g. phosphorylation of Thr509, Thr514 and Ser518 of CRMP is not detectable in cortex lacking GSK3β, yet normal in cortex lacking GSK3α). Furthermore, the neuron-enriched GSK3β2 variant phosphorylates phospho-glycogen synthase 2 peptide, CRMP2 (Thr509/514), CRMP4 (Thr509), Inhibitor-2 (Thr72) and tau (Ser396), at a lower rate than GSK3β1. In contrast phosphorylation of c-Myc and c-Jun is equivalent for each GSK3β isoform, providing evidence that differential substrate phosphorylation is achieved through alterations in expression and splicing of the GSK3 gene. Finally, each GSK3β splice variant is phosphorylated to a similar extent at the regulatory sites, Ser9 and Tyr216, and exhibit identical sensitivities to the ATP competitive inhibitor CT99021, suggesting upstream regulation and ATP binding properties of GSK3β1 and GSK3β2 are similar.

Original languageEnglish (US)
Pages (from-to)974-983
Number of pages10
JournalJournal of Neurochemistry
Volume115
Issue number4
DOIs
StatePublished - Nov 1 2010

Fingerprint

Glycogen Synthase Kinase 3
Brain
Protein Isoforms
Substrates
Phosphorylation
Neurons
Genes
Adenosine Triphosphate
Catenins
Glycogen Synthase

Keywords

  • CRMP
  • GSK3
  • Knockout
  • Neuron
  • Splice variant
  • Tau

ASJC Scopus subject areas

  • Biochemistry
  • Cellular and Molecular Neuroscience

Cite this

Soutar, M. P. M., Kim, W. Y., Williamson, R., Peggie, M., Hastie, C. J., McLauchlan, H., ... Sutherland, C. (2010). Evidence that glycogen synthase kinase-3 isoforms have distinct substrate preference in the brain. Journal of Neurochemistry, 115(4), 974-983. https://doi.org/10.1111/j.1471-4159.2010.06988.x

Evidence that glycogen synthase kinase-3 isoforms have distinct substrate preference in the brain. / Soutar, Marc P.M.; Kim, Woo Yang; Williamson, Ritchie; Peggie, Mark; Hastie, Charles James; McLauchlan, Hilary; Snider, William D.; Gordon-Weeks, Phillip R.; Sutherland, Calum.

In: Journal of Neurochemistry, Vol. 115, No. 4, 01.11.2010, p. 974-983.

Research output: Contribution to journalArticle

Soutar, MPM, Kim, WY, Williamson, R, Peggie, M, Hastie, CJ, McLauchlan, H, Snider, WD, Gordon-Weeks, PR & Sutherland, C 2010, 'Evidence that glycogen synthase kinase-3 isoforms have distinct substrate preference in the brain', Journal of Neurochemistry, vol. 115, no. 4, pp. 974-983. https://doi.org/10.1111/j.1471-4159.2010.06988.x
Soutar, Marc P.M. ; Kim, Woo Yang ; Williamson, Ritchie ; Peggie, Mark ; Hastie, Charles James ; McLauchlan, Hilary ; Snider, William D. ; Gordon-Weeks, Phillip R. ; Sutherland, Calum. / Evidence that glycogen synthase kinase-3 isoforms have distinct substrate preference in the brain. In: Journal of Neurochemistry. 2010 ; Vol. 115, No. 4. pp. 974-983.
@article{bedcd6e496144440aaec0cfa17877892,
title = "Evidence that glycogen synthase kinase-3 isoforms have distinct substrate preference in the brain",
abstract = "Mammalian glycogen synthase kinase-3 (GSK3) is generated from two genes, GSK3α and GSK3β, while a splice variant of GSK3β (GSK3β2), containing a 13 amino acid insert, is enriched in neurons. GSK3α and GSK3β deletions generate distinct phenotypes. Here, we show that phosphorylation of CRMP2, CRMP4, β-catenin, c-Myc, c-Jun and some residues on tau associated with Alzheimer's disease, is altered in cortical tissue lacking both isoforms of GSK3. This confirms that they are physiological targets for GSK3. However, deletion of each GSK3 isoform produces distinct substrate phosphorylation, indicating that each has a different spectrum of substrates (e.g. phosphorylation of Thr509, Thr514 and Ser518 of CRMP is not detectable in cortex lacking GSK3β, yet normal in cortex lacking GSK3α). Furthermore, the neuron-enriched GSK3β2 variant phosphorylates phospho-glycogen synthase 2 peptide, CRMP2 (Thr509/514), CRMP4 (Thr509), Inhibitor-2 (Thr72) and tau (Ser396), at a lower rate than GSK3β1. In contrast phosphorylation of c-Myc and c-Jun is equivalent for each GSK3β isoform, providing evidence that differential substrate phosphorylation is achieved through alterations in expression and splicing of the GSK3 gene. Finally, each GSK3β splice variant is phosphorylated to a similar extent at the regulatory sites, Ser9 and Tyr216, and exhibit identical sensitivities to the ATP competitive inhibitor CT99021, suggesting upstream regulation and ATP binding properties of GSK3β1 and GSK3β2 are similar.",
keywords = "CRMP, GSK3, Knockout, Neuron, Splice variant, Tau",
author = "Soutar, {Marc P.M.} and Kim, {Woo Yang} and Ritchie Williamson and Mark Peggie and Hastie, {Charles James} and Hilary McLauchlan and Snider, {William D.} and Gordon-Weeks, {Phillip R.} and Calum Sutherland",
year = "2010",
month = "11",
day = "1",
doi = "10.1111/j.1471-4159.2010.06988.x",
language = "English (US)",
volume = "115",
pages = "974--983",
journal = "Journal of Neurochemistry",
issn = "0022-3042",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Evidence that glycogen synthase kinase-3 isoforms have distinct substrate preference in the brain

AU - Soutar, Marc P.M.

AU - Kim, Woo Yang

AU - Williamson, Ritchie

AU - Peggie, Mark

AU - Hastie, Charles James

AU - McLauchlan, Hilary

AU - Snider, William D.

AU - Gordon-Weeks, Phillip R.

AU - Sutherland, Calum

PY - 2010/11/1

Y1 - 2010/11/1

N2 - Mammalian glycogen synthase kinase-3 (GSK3) is generated from two genes, GSK3α and GSK3β, while a splice variant of GSK3β (GSK3β2), containing a 13 amino acid insert, is enriched in neurons. GSK3α and GSK3β deletions generate distinct phenotypes. Here, we show that phosphorylation of CRMP2, CRMP4, β-catenin, c-Myc, c-Jun and some residues on tau associated with Alzheimer's disease, is altered in cortical tissue lacking both isoforms of GSK3. This confirms that they are physiological targets for GSK3. However, deletion of each GSK3 isoform produces distinct substrate phosphorylation, indicating that each has a different spectrum of substrates (e.g. phosphorylation of Thr509, Thr514 and Ser518 of CRMP is not detectable in cortex lacking GSK3β, yet normal in cortex lacking GSK3α). Furthermore, the neuron-enriched GSK3β2 variant phosphorylates phospho-glycogen synthase 2 peptide, CRMP2 (Thr509/514), CRMP4 (Thr509), Inhibitor-2 (Thr72) and tau (Ser396), at a lower rate than GSK3β1. In contrast phosphorylation of c-Myc and c-Jun is equivalent for each GSK3β isoform, providing evidence that differential substrate phosphorylation is achieved through alterations in expression and splicing of the GSK3 gene. Finally, each GSK3β splice variant is phosphorylated to a similar extent at the regulatory sites, Ser9 and Tyr216, and exhibit identical sensitivities to the ATP competitive inhibitor CT99021, suggesting upstream regulation and ATP binding properties of GSK3β1 and GSK3β2 are similar.

AB - Mammalian glycogen synthase kinase-3 (GSK3) is generated from two genes, GSK3α and GSK3β, while a splice variant of GSK3β (GSK3β2), containing a 13 amino acid insert, is enriched in neurons. GSK3α and GSK3β deletions generate distinct phenotypes. Here, we show that phosphorylation of CRMP2, CRMP4, β-catenin, c-Myc, c-Jun and some residues on tau associated with Alzheimer's disease, is altered in cortical tissue lacking both isoforms of GSK3. This confirms that they are physiological targets for GSK3. However, deletion of each GSK3 isoform produces distinct substrate phosphorylation, indicating that each has a different spectrum of substrates (e.g. phosphorylation of Thr509, Thr514 and Ser518 of CRMP is not detectable in cortex lacking GSK3β, yet normal in cortex lacking GSK3α). Furthermore, the neuron-enriched GSK3β2 variant phosphorylates phospho-glycogen synthase 2 peptide, CRMP2 (Thr509/514), CRMP4 (Thr509), Inhibitor-2 (Thr72) and tau (Ser396), at a lower rate than GSK3β1. In contrast phosphorylation of c-Myc and c-Jun is equivalent for each GSK3β isoform, providing evidence that differential substrate phosphorylation is achieved through alterations in expression and splicing of the GSK3 gene. Finally, each GSK3β splice variant is phosphorylated to a similar extent at the regulatory sites, Ser9 and Tyr216, and exhibit identical sensitivities to the ATP competitive inhibitor CT99021, suggesting upstream regulation and ATP binding properties of GSK3β1 and GSK3β2 are similar.

KW - CRMP

KW - GSK3

KW - Knockout

KW - Neuron

KW - Splice variant

KW - Tau

UR - http://www.scopus.com/inward/record.url?scp=77958597709&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77958597709&partnerID=8YFLogxK

U2 - 10.1111/j.1471-4159.2010.06988.x

DO - 10.1111/j.1471-4159.2010.06988.x

M3 - Article

C2 - 20831597

AN - SCOPUS:77958597709

VL - 115

SP - 974

EP - 983

JO - Journal of Neurochemistry

JF - Journal of Neurochemistry

SN - 0022-3042

IS - 4

ER -